Long-term safety of facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases: final analysis from a post-authorization safety study conducted in the USAArye Rubinstein, Leman Yel, Niraj Patel et al.|Clinical Immunology|2023Cited by 1
60 Assessing hyaluronidase-facilitated subcutaneous immunoglobulin 20% (fSCIG 20%) pharmacokinetics, safety and tolerability in primary immunodeficiency diseases: phase 2/3 study designRichard LWasserman, Zhaoyang Li, András Nagy et al.|Clinical Immunology|2024Cited by 0